---
title: "Evolus partners with IBSA to license, distribute Profhilo in US"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292072481.md"
description: "Evolus has entered an exclusive licensing and distribution agreement with Switzerland's IBSA to develop and commercialize Profhilo, a hyaluronic acid injectable for skin quality, in the US. Evolus will handle regulatory approval and leverage its existing sales infrastructure for commercialization. The deal involves no upfront payments and utilizes a transfer-price model. Evolus expects no impact on its 2026 outlook or long-term revenue and profitability targets."
datetime: "2026-07-08T13:02:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292072481.md)
  - [en](https://longbridge.com/en/news/292072481.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292072481.md)
generator: "portal-rs"
---

# Evolus partners with IBSA to license, distribute Profhilo in US

-   Evolus entered an exclusive licensing and distribution deal with Switzerland’s IBSA to develop and commercialize Profhilo in the US. \* Profhilo is a hyaluronic acid injectable positioned for skin quality; more than 4,800,000 treatments have been administered globally since 2015. \* Evolus will run US development for regulatory approval, then lead commercialization using its existing sales and digital infrastructure. \* Deal includes no upfront payments; economics use a transfer-price model targeting gross margins consistent with Evolus’ long-term framework. \* Evolus expects no change to its 2026 outlook or its previously stated 2028 revenue and profitability targets. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evolus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260708437892) on July 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [EOLS.US](https://longbridge.com/en/quote/EOLS.US.md)

## Related News & Research

- [Evolus posts scientific investor presentation on Jeuveau, Evolysse HA fillers, Profhilo skin-quality injectable portfolio](https://longbridge.com/en/news/295023087.md)
- [Turn Therapeutics says mouse study shows GX-03 cuts dermatitis severity 66%](https://longbridge.com/en/news/296487429.md)
- [3 Next-Gen AI Stocks That 3G Capital Bought in Q2](https://longbridge.com/en/news/296496173.md)
- [Amorepacific derma brand AESTURA presents AI skin analysis research at KDD 2026 in Jeju](https://longbridge.com/en/news/295897314.md)
- [KTH Ventures invests in Samplimy Medical in minority stake deal](https://longbridge.com/en/news/296626556.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**